Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Korakis I"'
Autor:
Morisseau M; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud- IUCT-O, 1 Avenue Irène Joliot-Curie, Toulouse, Cedex 9, 31059, France., Gomez-Roca C; Department of Medical Oncology, Oncopole Claudius Regaud- IUCT-O, Toulouse, France., Viala M; Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Montpellier, France., Rabeau A; Department of Pneumology, CHU Toulouse Larrey, Toulouse, France., Loirat D; Department of Medical Oncology, Institut Curie, Paris, Saint-Cloud, France.; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France., Munsch N; Department of Medical Oncology, CH Albi, Albi, France., Thomas K; Department of Medical Oncology, Oncopole Claudius Regaud- IUCT-O, Toulouse, France., Pages C; Department of Dermatology Oncology, Oncopole Claudius Regaud- IUCT-O, Toulouse, France., Korakis I; Department of Medical Oncology, Oncopole Claudius Regaud- IUCT-O, Toulouse, France., Sibaud V; Department of Dermatology Oncology, Oncopole Claudius Regaud- IUCT-O, Toulouse, France., Delord JP; Department of Medical Oncology, Oncopole Claudius Regaud- IUCT-O, Toulouse, France., Filleron T; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud- IUCT-O, 1 Avenue Irène Joliot-Curie, Toulouse, Cedex 9, 31059, France. filleron.thomas@iuct-oncopole.fr.; Université Paris-Saclay, CESP, INSERM U1018 Oncostat, labeled Ligue Contre le Cancer, Villejuif, France. filleron.thomas@iuct-oncopole.fr., Cabarrou B; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud- IUCT-O, 1 Avenue Irène Joliot-Curie, Toulouse, Cedex 9, 31059, France.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2024 Nov 04. Date of Electronic Publication: 2024 Nov 04.
Autor:
Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Saada-Bouzid E; Department of Medical Oncology, Cote d'Azur University, Centre Antoine Lacassagne, Nice, France., Longo F; Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, Centro de Investigación Biomédica en Red Cáncer, Alcalá University, Madrid, Spain., Yanez E; Oncology-Hematology Unit, University of Frontera, Araucanía, Chile., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Castanon E; Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain., Desautels DN; Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada., Graham DM; Experimental Cancer Medicine Team, The Christie National Health Service Foundation Trust, Manchester, UK.; University of Manchester, Manchester, UK., Garcia-Corbacho J; Clinical Institute of Hemato-Oncological Diseases, Hospital Clinic, Barcelona, Spain., Lopez J; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK., Dutcus C; Eisai Inc., Nutley, New Jersey, USA., Okpara CE; Eisai Ltd., Hatfield, UK., Ghori R; Merck & Co., Inc., Rahway, New Jersey, USA., Jin F; Merck & Co., Inc., Rahway, New Jersey, USA., Groisberg R; Merck & Co., Inc., Rahway, New Jersey, USA., Korakis I; Department of Medicine and Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse, France.
Publikováno v:
Cancer [Cancer] 2024 Oct 01; Vol. 130 (19), pp. 3278-3288. Date of Electronic Publication: 2024 Jun 21.
Autor:
Poumeaud F; Department of Medical Oncology, Oncopole Claudius Regaud, Toulouse, France., Jaffrelot M; Department of Digestive Oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Gomez-Roca C; Clinical Research Unit, Department of Medical Oncology, Oncopole Claudius Regaud, Toulouse, France., Korakis I; Clinical Research Unit, Department of Medical Oncology, Oncopole Claudius Regaud, Toulouse, France., Leonardi G; Clinical Research Unit, Department of Medical Oncology, Oncopole Claudius Regaud, Toulouse, France., Joly M; Department of Infectiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Mazières J; Department of Thoracic Oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Guimbaud R; Department of Digestive Oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Fares N; Department of Digestive Oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.; Clinical Research Unit, Department of Medical Oncology, Oncopole Claudius Regaud, Toulouse, France., Alouani E; Department of Digestive Oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.; Clinical Research Unit, Department of Medical Oncology, Oncopole Claudius Regaud, Toulouse, France.
Publikováno v:
Frontiers in medicine [Front Med (Lausanne)] 2024 Jul 30; Vol. 11, pp. 1402902. Date of Electronic Publication: 2024 Jul 30 (Print Publication: 2024).
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Voissière A; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France., Gomez-Roca C; Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Chabaud S; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Rodriguez C; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Nkodia A; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Berthet J; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Montane L; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Bidaux AS; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Treilleux I; Biopathology Department, Centre Léon Bérard, Lyon, France., Eberst L; Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, Lyon, France., Terret C; Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, Lyon, France., Korakis I; Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Garin G; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Pérol D; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Delord JP; Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Caux C; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Dubois B; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Ménétrier-Caux C; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Bendriss-Vermare N; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Cassier PA; Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, Lyon, France.
Publikováno v:
Science translational medicine [Sci Transl Med] 2024 Jan 24; Vol. 16 (731), pp. eadd1834. Date of Electronic Publication: 2024 Jan 24.
Autor:
Vieito, M., Mckean, M., Spira, A.I., Rosen, E., Rodon, J., Moreno Garcia, V., Gambardella, V., Saavedra, O., Cousin, S., Cassier, P., Korakis, I., Van Tine, B.A., Ma, V.T-L., Ali, A., Hinojosa, E., Lobbardi, R., Liu, H., Hurh, E., Reyno, L., Buchbinder, E.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S490-S491
Autor:
Cousin, S., Bellera, C., Guegan, J-P., Valentin, T., Verret, B., Metges, J-P., Adenis, A., Cassier, P., Bouteiller, F., Ceruso, M. Spalato, Korakis, I., Hollebecque, A., Poureau, P.G., Palussiere, J., Kind, M., Soubeyran, I., Bessede, A., Italiano, A.
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S1033-S1033
Autor:
Polito, M., Le Tourneau, C., DeMontfort, A., Cousin, S., Toulmonde, M., Gomez-Roca, C.A., Bourcier, K., Korakis, I., Bertucci, F., Mitry, E., Mazza, C., Cassier, P., Coutzac, C., Italiano, A., Attignon, V.K., Mayet, R., Perol, D., Sablin, M.P., Blay, J-Y., Tredan, O.
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S236-S236
Autor:
Vano YA; Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP Centre-Université Paris Cité, Paris, France.; INSERM U970, PARCC, Paris, France.; Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, France., Phan L; ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP Centre, Paris, France., Gravis G; Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France., Korakis I; Medical Oncology, Institut Universitaire du Cancer-Toulouse-Oncopole, Toulouse, France., Schlürmann F; Medical Oncology, Centre Hospitalier Intercommunal, Quimper, Quimper, France., Maillet D; Medical Oncology, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon (IC-HCL), Pierre-Bénite, France., Bennamoun M; Medical Oncology, Institut Mutualiste Montsouris, Paris, France., Houede N; Medical Oncology, Institut de cancérologie du Gard, Nimes, Montpellier University, France., Topart D; Medical Oncology, Hopital Saint-Eloi (CHU de Montpellier), Montpellier, France., Borchiellini D; Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., Barthelemy P; Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Ratta R; Medical Oncology, Hopital Foch, Suresnes, France., Ryckewaert T; Medical Oncology, Centre Oscar Lambret, Lille, France., Hasbini A; Medical Oncology, Clinique Pasteur Lanroze, Brest, France., Hans S; Department of Medical Oncology, Hôpital Henri-Mondor, AP-HP-Université de Paris Est, Créteil, France., Emambux S; Medical Oncology, Centre Hospitalier Universitaire Poitiers, Poitiers, France., Cournier S; ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP Centre, Paris, France., Braychenko E; ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP Centre, Paris, France., Elaidi RT; ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP Centre, Paris, France., Oudard S; Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP Centre-Université Paris Cité, Paris, France.; INSERM U970, PARCC, Paris, France.
Publikováno v:
International journal of cancer [Int J Cancer] 2022 Oct 15; Vol. 151 (8), pp. 1335-1344. Date of Electronic Publication: 2022 Jun 06.
Autor:
Cousin S; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France., Cantarel C; Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France., Guegan JP; Explicyte, 229 Cours de L'Argonne, Bordeaux, France., Mazard T; Department of Medical Oncology, Institut Regional Du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France., Gomez-Roca C; Department of Medical Oncology, IUCT, 1 Avenue Irène Joliot-Curie, 31100, Toulouse, France., Metges JP; Department of Medical Oncology, CHRU de Brest - Hôpital Morvan, 2 Avenue Foch, 29609, Brest, France., Bellera C; Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France; Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000, Bordeaux, France., Adenis A; Department of Medical Oncology, Institut Regional Du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France., Korakis I; Department of Medical Oncology, IUCT, 1 Avenue Irène Joliot-Curie, 31100, Toulouse, France., Poureau PG; Department of Medical Oncology, CHRU de Brest - Hôpital Morvan, 2 Avenue Foch, 29609, Brest, France., Bourcier K; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France., Toulmonde M; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France., Kind M; Department of Radiology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France., Rey C; Explicyte, 229 Cours de L'Argonne, Bordeaux, France., Auzanneau C; Department of Biopathology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France., Bessede A; Explicyte, 229 Cours de L'Argonne, Bordeaux, France., Soubeyran I; Department of Biopathology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France., Italiano A; Early Phase Trials Unit, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France; University of Bordeaux, Bordeaux, France; Gustave Roussy, Villejuif, France. Electronic address: a.italiano@bordeaux.unicancer.fr.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Feb; Vol. 162, pp. 161-169. Date of Electronic Publication: 2022 Jan 05.